Clinical Trial

A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region

Study acronym: ASC4Young
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the real-world effectiveness and safety of asciminib among young adults with chronic myeloid leukemia (CML) across the Gulf region. The data source for this study will consist of routinely collected clinical information documented within the electronic health records (EHR) of participating centers.
Trial Details
NCT Number NCT07681258
Lead Sponsor Novartis Pharmaceuticals
Conditions Chronic Myeloid Leukemia
Enrollment 80 participants
Start Date 2026-06-30
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-02